Skip to main content

Ken Myszkowski

Equibles does not estimate personal net worth.

About Ken Myszkowski

Earlier roles on record: CFO at Arrowhead Pharmaceuticals, Inc. (ARWR) until May 13, 2025. Arrowhead Pharmaceuticals, Inc. reported in an 8-K filed April 15, 2025 that Ken Myszkowski retired as Chief Financial Officer, effective May 13, 2025. Ken Myszkowski has spoken on 19 earnings calls across 1 company, most recently for Arrowhead Pharmaceuticals, Inc. on February 10, 2025. The companies whose calls Ken Myszkowski spoke on are classified in the Healthcare sector.

“On, April 9, 2025 Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the "Company") of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025 (the "Effective Date").”
Arrowhead Pharmaceuticals, Inc. Form 8-K, filed April 15, 2025 · Read the filing

Ken Myszkowski on recent calls

“As we reported today, our net loss for the quarter ended December 31, 2024, was $173.1 million or $1.39 per share based on 124.8 million fully diluted weighted average shares outstanding.”
CFO, Arrowhead Pharmaceuticals, Inc. Q1 FY2025 Earnings Call ·
“As we reported today, our net loss for fiscal 2024 was $599.5 million or $5 per share based on $119.8 million fully diluted weighted average shares outstanding.”
CFO, Arrowhead Pharmaceuticals, Inc. Q4 FY2024 Earnings Call ·
“As we reported today, our net loss for the quarter ended June 30, 2024, was $170.8 million or $1.38 per share based on $124.2 million fully diluted weighted average shares outstanding.”
CFO, Arrowhead Pharmaceuticals, Inc. Q3 FY2024 Earnings Call ·
“As we reported today, our net loss for the quarter ended March 31, 2024, was $125.3 million or $1.02 per share based on 123.3 million fully diluted weighted average shares outstanding.”
CFO, Arrowhead Pharmaceuticals, Inc. Q2 FY2024 Earnings Call ·
“As we reported today, our net loss for the quarter ended December 31, 2023, was $132.9 million or $1.24 per share, based on $107.4 million fully diluted weighted average shares outstanding.”
CFO, Arrowhead Pharmaceuticals, Inc. Q1 FY2024 Earnings Call ·

Affiliation history

Company network

Recent activity

Show 8 earlier activities